Rare Donor Program
In 2004, LifeShare’s Board of Trustees adopted a resolution to name the laboratories for world-renowned serologist and immunohematologist John J. Moulds, MT(ASCP)SBB.
Mr. Moulds joined LifeShare in 2004, bringing with him the expertise and wisdom of a highly distinguished career in immunohematology. In addition to his expert contributions to the laboratory and creation of the Scientific Support division, Mr. Moulds donated his extens
LifeShare’s research indicates populations within our service area have a higher incidence of rare characteristics compared to other regional populations. Donors with these unique characteristics are especially important to patients who have complex blood compatibility issues. As a result of our efforts in donor screening, LifeShare has been extremely successful in providing for the needs of our patient population as well as the needs of many problematic patients across the country. LifeShare is a major contributor to the American Rare Donor Program with which we have collaborated to send hundreds of rare units across the US and even overseas. LifeShare also takes on special cases for patients in other states where we act as the primary supplier for treatment regimens involving patients with rare blood requirements.
Typically, a rare donor is a person whose red blood cells have been tested and found to lack a certain high-incidence antigen or a combination of several more common antigens which together make the blood unique. Certain patients need blood from a rare donor for compatibility because they have produced red cell antibodies and require a more specific match than just A, B or O.
To best meet the needs of patients in our community and abroad, LifeShare Blood Centers regularly screens donated blood for these unique characteristics. Donors of all types are in demand to manage the needs in our area, but they may also be helpful in saving a life hundreds or thousands of miles away. By having a safe and adequate blood supply available to the community, it allows us to screen and save rare blood units for those patients who specifically require them. Blood is an invaluable commodity with limited resources and the supply must be managed carefully. Most patients will not produce red cell antibodies and won’t require the use of specially screened blood. However, all it takes is one patient with a special need to make our rare donor program worthwhile.
ANTIGENS, ANTIBODIES AND THE RARE DONOR PROGRAM
To understand the rare donor program, one must first understand a few basic concepts:
What is an antigen? An antigen is a structure (either sugar or protein) found on a red blood cell which is capable of stimulating the immune system to produce an antibody. When an antigen is found on the red blood cells of most people, it is called a high-incidence antigen. When an antigen has been shown to be absent from most people, it is called a low-incidence antigen.
What is an antibody? An antibody is a protein made by the immune system as a result of the body coming into contact with an antigen it does not recognize. When foreign substances enter the body, the immune system may make antibodies to those substances, but it is not guaranteed.
Who needs rare blood? When a patient receives blood, there is a possibility minute differences in the donor blood can result in an immune response by the patient’s immune system, whereby antibodies are produced against those differences (foreign antigens) in an effort to protect the patient from what the body perceives as an invading substance. Individuals, who produce an antibody or antibodies, are called “Responders.” The incidence of “Responders” are generally only about 3% in the general population, so most people are never going to make any antibodies and will not require anything special regarding blood transfusion even if they are found to be negative for a high-incidence antigen.
Some factors can increase the “Responder” incidence. Repeated exposure to different blood cells other than your own (i.e., by transfusion or pregnancy) will increase the chance of antibody production. Patients who are regularly transfused as a part of treatment, thus, repeatedly exposed to many different types of red blood cells, such as Sickle Cell or Thalassemia patients, are more likely to produce antibodies while persons transfused once or twice in a lifetime are not as likely. Sickle Cell Disease in itself is considered a “hyper-immune” condition which also enhances the likelihood of antibody production, in these patients.
Providing Rare Donor Blood
In most cases, antibodies produced will result in slight delays regarding transfusion as blood required cannot just be taken off the “shelf” as A, B, O, etc., but must first be screened for one or two common antigens to make sure it will not react with the antibody produced. In rare cases, the antibody a patient produces reacts with almost all donor cells it comes in contact with and only a small percentage of the population (usually less than 1%) will end up being an acceptable transfusion match for the patient. This results from a patient producing multiple antibodies to several common antigens or an antibody to a high incidence antigen.
In years past, the only way to find such rare donors was to take patient serum containing the rare antibody and test it against all possible donor samples and hope for a match. This testing can take hours to complete, is fairly labor intensive and requires a large amount of patient plasma. Today, DNA testing provides a cost-effective complimentary tool for identifying rare donors and one day it may overtake traditional screening as the method of choice for this testing.
Rare Donor Program at LifeShare Blood Centers
Screening for rare donors at LifeShare Blood Centers has been a phenomenal success and major blessing for our community and for many unique patient needs across the country. LifeShare staff have currently screened over 90,000 donors for rare blood types (beyond A, B, and O using both traditional and DNA testing), classifying close to a thousand of those as rare donors.
As a result of this, LifeShare is one of the leading providers of rare blood through a special endeavor named the American Rare Donor Program, which is a collaborative program between the American Red Cross and AABB Immunohematology Reference Laboratories designed to meet the needs of very unique patients throughout the country and occasionally beyond our borders.
Matching Rare Donors with Patients in Need
Rare blood types exist in every population. To find a matching blood type for a unique patient in need, the best outcomes are nearly always found from a donor within the same ethnic population to which the patient belongs. The LifeShare service area is made up of mostly Caucasian (white) and African-descent (black) individuals. To best serve our communities, LifeShare laboratory staff regularly screen donors for known rarities most common in these populations.
Once donors are found to possess one of these rare types, LifeShare staff can match the donor with specific patients requiring certain types of rare blood. Ten years ago, matched units for many of these patients required national searches and took weeks or months to find the appropriate units, if any were found at all. Currently, LifeShare is able to fill rare unit requests in a matter of days generally, and most often from blood drawn at one of our own collection centers. Additionally, we are able to meet the needs of many exceedingly rare patients across the country due to our screening efforts and the generosity and dedication of the rare donors we have identified.
Rare Donors and Sickle Cell Patients
The LifeShare service area provides care for a number of patients with Sickle Cell Disease. Due to the nature of this disease, matched donor blood is often necessary but difficult to find because of the production of rare or multiple antibody combinations. The treatment for these patients often is based on blood transfusions. Sickle cell patients nearly always require blood that is tested for unique characteristics either to match for antibodies already produced or to reduce the chances of antibody production over their treatment. It is our goal to expand our donor base and continue to identify rare donors to meet the needs of these special patient populations in our communities.
ive collection of rare reference cells to LifeShare.
With this contribution, LifeShare’s rare reference cell collection became one of the largest in the world.
The laboratories were formally dedicated on February 19, 2011, as the John J. Moulds Reference and Scientific Support Laboratories. Mr. Moulds passed away later that same year. We, at LifeShare Blood Centers, will never forget him and work to carry on his great legacy.
Human Umbilical Vein Endothelial Cells (HUVEC)
20C or in vapor state LN2 until ready to use
20C or in vapor state LN2 until ready to use
Products are tested and found to be negative for mycoplasma and endotoxin.
Donor tested and found to be negative for HIV 1, HIV 2, Hepatitis B, Hepatitis C, HTLV 1, WNV, Zika, and Syphilis
Human umbilical vein endothelial cells (HUVEC) are primary cells isolated from the vein of the umbilical cord. They are a model system for studying endothelial cell function, with applications including hypoxia, inflammation, oxidative stress, response to infection, and both normal and tumor-associated angiogenesis.